Pfizer Inc. $PFE Shares Sold by Diamond Hill Capital Management Inc.

Diamond Hill Capital Management Inc. cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 9,439,267 shares of the biopharmaceutical company’s stock after selling 1,485,000 shares during the period. Diamond Hill Capital Management Inc.’s holdings in Pfizer were worth $235,038,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Van Hulzen Asset Management LLC increased its holdings in shares of Pfizer by 46.3% in the 4th quarter. Van Hulzen Asset Management LLC now owns 35,991 shares of the biopharmaceutical company’s stock valued at $896,000 after acquiring an additional 11,382 shares during the last quarter. Signature Estate & Investment Advisors LLC increased its holdings in shares of Pfizer by 4.1% in the 4th quarter. Signature Estate & Investment Advisors LLC now owns 25,328 shares of the biopharmaceutical company’s stock valued at $631,000 after acquiring an additional 1,002 shares during the last quarter. Commonwealth Financial Services LLC increased its holdings in shares of Pfizer by 1.3% in the 4th quarter. Commonwealth Financial Services LLC now owns 38,927 shares of the biopharmaceutical company’s stock valued at $969,000 after acquiring an additional 514 shares during the last quarter. Hexagon Capital Partners LLC increased its holdings in shares of Pfizer by 5.9% in the 4th quarter. Hexagon Capital Partners LLC now owns 58,939 shares of the biopharmaceutical company’s stock valued at $1,468,000 after acquiring an additional 3,261 shares during the last quarter. Finally, Global Retirement Partners LLC increased its holdings in shares of Pfizer by 60.6% in the 4th quarter. Global Retirement Partners LLC now owns 216,502 shares of the biopharmaceutical company’s stock valued at $5,391,000 after acquiring an additional 81,713 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Trading Up 0.5%

Shares of PFE stock opened at $25.93 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. Pfizer Inc. has a 1 year low of $22.81 and a 1 year high of $28.75. The stock has a fifty day moving average of $26.88 and a two-hundred day moving average of $26.23. The firm has a market capitalization of $147.76 billion, a PE ratio of 19.79 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.99 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Stockholders of record on Friday, May 8th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 annualized dividend and a dividend yield of 6.6%. Pfizer’s dividend payout ratio is 131.30%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on PFE shares. Cantor Fitzgerald reiterated a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a report on Wednesday, February 4th. Wall Street Zen upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, May 6th. Bank of America lowered their price target on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Finally, Barclays began coverage on Pfizer in a research note on Thursday, February 19th. They set an “underweight” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, Pfizer currently has an average rating of “Hold” and an average price target of $28.61.

Key Stories Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced strong Phase 2 results for its investigational 25-valent pneumococcal vaccine in infants, including a stronger immune response than Prevnar 20 and up to 15-fold higher antibody levels against a key strain. The company is now moving the program into pivotal Phase 3 testing, which could support future vaccine growth. Article Title
• Positive Sentiment: The company also received a broader European indication for HYMPAVZI, adding another recent R&D win that may strengthen Pfizer’s hemophilia franchise and improve investor confidence in the pipeline. Article Title
• Positive Sentiment: Pfizer and Rigel Pharmaceuticals expanded a commercialization deal for VEPPANU (vepdegestrant), creating another potential partnership-driven revenue stream tied to oncology. Article Title
• Positive Sentiment: Pfizer’s oncology growth story is also getting attention, with coverage pointing to Padcev, biosimilars, and late-stage pipeline assets as key long-term drivers. Article Title
• Neutral Sentiment: Pfizer was also listed as a participant in an AI industry summit, but this appears unrelated to the company’s core investment thesis and is unlikely to move the stock on its own. Article Title

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.